ANS-858 is being developed to reduce pathological craving associated with alcohol and other substance use disorders.
Animal trials show cartilage repair within four weeks following a single injection of chondrocyte spheroids
Filing targets TPN, propofol and other IV therapies where undetected infiltration
and extravasation can cause severe injury
PROVIDENCE, R.I., Aug. 18, 2026 /PRNewswire/ — GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, announced today that new data from a multi-institutional feasibility clinical trial across 15 institutions nationwide presented by Clark Chen, M.D., Ph.D., professor and director of the Brain Tumor Program at Brown University Health, suggest that a novel radiation therapy device may help improve outcomes for patients newly diagnosed with glioblastoma, one of the deadliest forms of brain cancer.
Expanded indication enables clinicians to detect sarcopenia risk from the same rapid SOZO scan, supporting earlier intervention in cancer care.